Humira Biosimilar Adoption Starts Slow In Medicare
US Medicare Payment Advisory Commission will be tracking adoption of Humira biosimilars – both because of the direct impact on costs in the Part D program, but also to test whether changes to the benefit design will work to encourage price competition.
